Industry Research Reports

Home > Reports > Pharma & Healthcare > Anticancer Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Anticancer Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-04-02

Pages: 128 Pages

Report ld: 2670172

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Anticancer drugs are medications used to treat cancer by targeting and killing cancer cells or inhibiting their growth. Anticancer drugs are medications specifically designed to combat cancer by either inhibiting the growth of cancer cells or inducing their death. These drugs operate through various mechanisms, such as disrupting the cell cycle, interfering with specific signaling pathways crucial for cancer cell survival, or targeting the blood vessels that support tumor growth. Anticancer drugs encompass a diverse range of classes, including cytotoxic drugs, targeted therapies, hormone therapies, immunotherapies, and angiogenesis inhibitors. The selection of these drugs depends on the type of cancer, its stage, and individual patient characteristics. While these medications play a crucial role in cancer treatment, they may also have side effects due to their impact on rapidly dividing normal cells.

 The global market for Anticancer Drugs was estimated to be worth US$ 190010 million in 2023 and is forecast to a readjusted size of US$ 390920 million by 2030 with a CAGR of 11.3% during the forecast period 2024-2030.

Anticancer Drugs Market Size

M= millions and B=billions

Global key players of Anticancer Drugs include Merck & Co, Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, etc. The top five players hold a share over 55%. North America is the largest market, and has a share about 55%, followed by Asia-Pacific and Europe with share 21% and 19%, separately. In terms of product type, Targeted Therapy is the largest segment, occupied for a share of 58%. In terms of application, Blood-related Cancer has a share about 23 percent.

The Anticancer Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anticancer Drugs.

Market Segmentation

Report Metric
Details
Report Title
Anticancer Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 390920 million
CAGR(2024-2030)
11.3%
Market Size Available for Years
2019-2030
Global Anticancer Drugs Companies Covered
AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine
Global Anticancer Drugs Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anticancer Drugs Market, Segment by Type
Cancer Immunotherapy

Targeted Therapy

Chemotherapy

Other
Global Anticancer Drugs Market, Segment by Application
Lung Cancer

Breast Cancer

Prostate Cancer

Blood-related Cancer

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Anticancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Anticancer Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Anticancer Drugs Product Introduction
    1.2 Global Anticancer Drugs Market Size Forecast (2019-2030)
    1.3 Anticancer Drugs Market Trends & Drivers
        1.3.1 Anticancer Drugs Industry Trends
        1.3.2 Anticancer Drugs Market Drivers & Opportunity
        1.3.3 Anticancer Drugs Market Challenges
        1.3.4 Anticancer Drugs Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Anticancer Drugs Players Revenue Ranking (2023)
    2.2 Global Anticancer Drugs Revenue by Company (2019-2024)
    2.3 Key Companies Anticancer Drugs Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Anticancer Drugs Product Offered
    2.5 Key Companies Time to Begin Mass Production of Anticancer Drugs
    2.6 Anticancer Drugs Market Competitive Analysis
        2.6.1 Anticancer Drugs Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Anticancer Drugs Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anticancer Drugs as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Cancer Immunotherapy
        3.1.2 Targeted Therapy
        3.1.3 Chemotherapy
        3.1.4 Other
    3.2 Global Anticancer Drugs Sales Value by Type
        3.2.1 Global Anticancer Drugs Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Anticancer Drugs Sales Value, by Type (2019-2030)
        3.2.3 Global Anticancer Drugs Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Lung Cancer
        4.1.2 Breast Cancer
        4.1.3 Prostate Cancer
        4.1.4 Blood-related Cancer
        4.1.5 Other
    4.2 Global Anticancer Drugs Sales Value by Application
        4.2.1 Global Anticancer Drugs Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Anticancer Drugs Sales Value, by Application (2019-2030)
        4.2.3 Global Anticancer Drugs Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Anticancer Drugs Sales Value by Region
        5.1.1 Global Anticancer Drugs Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Anticancer Drugs Sales Value by Region (2019-2024)
        5.1.3 Global Anticancer Drugs Sales Value by Region (2025-2030)
        5.1.4 Global Anticancer Drugs Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Anticancer Drugs Sales Value, 2019-2030
        5.2.2 North America Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Anticancer Drugs Sales Value, 2019-2030
        5.3.2 Europe Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Anticancer Drugs Sales Value, 2019-2030
        5.4.2 Asia Pacific Anticancer Drugs Sales Value by Region (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Anticancer Drugs Sales Value, 2019-2030
        5.5.2 South America Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Anticancer Drugs Sales Value, 2019-2030
        5.6.2 Middle East & Africa Anticancer Drugs Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Anticancer Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Anticancer Drugs Sales Value, 2019-2030
    6.3 United States
        6.3.1 United States Anticancer Drugs Sales Value, 2019-2030
        6.3.2 United States Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Anticancer Drugs Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Anticancer Drugs Sales Value, 2019-2030
        6.4.2 Europe Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Anticancer Drugs Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Anticancer Drugs Sales Value, 2019-2030
        6.5.2 China Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Anticancer Drugs Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Anticancer Drugs Sales Value, 2019-2030
        6.6.2 Japan Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Anticancer Drugs Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Anticancer Drugs Sales Value, 2019-2030
        6.7.2 South Korea Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Anticancer Drugs Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Anticancer Drugs Sales Value, 2019-2030
        6.8.2 Southeast Asia Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Anticancer Drugs Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Anticancer Drugs Sales Value, 2019-2030
        6.9.2 India Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Anticancer Drugs Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 AbbVie
        7.1.1 AbbVie Profile
        7.1.2 AbbVie Main Business
        7.1.3 AbbVie Anticancer Drugs Products, Services and Solutions
        7.1.4 AbbVie Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.1.5 AbbVie Recent Developments
    7.2 Johnson & Johnson
        7.2.1 Johnson & Johnson Profile
        7.2.2 Johnson & Johnson Main Business
        7.2.3 Johnson & Johnson Anticancer Drugs Products, Services and Solutions
        7.2.4 Johnson & Johnson Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.2.5 Johnson & Johnson Recent Developments
    7.3 Novartis
        7.3.1 Novartis Profile
        7.3.2 Novartis Main Business
        7.3.3 Novartis Anticancer Drugs Products, Services and Solutions
        7.3.4 Novartis Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.3.5 Novartis Recent Developments
    7.4 Gilead Sciences
        7.4.1 Gilead Sciences Profile
        7.4.2 Gilead Sciences Main Business
        7.4.3 Gilead Sciences Anticancer Drugs Products, Services and Solutions
        7.4.4 Gilead Sciences Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.4.5 Gilead Sciences Recent Developments
    7.5 Roche
        7.5.1 Roche Profile
        7.5.2 Roche Main Business
        7.5.3 Roche Anticancer Drugs Products, Services and Solutions
        7.5.4 Roche Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.5.5 Roche Recent Developments
    7.6 Bristol-Myers Squibb
        7.6.1 Bristol-Myers Squibb Profile
        7.6.2 Bristol-Myers Squibb Main Business
        7.6.3 Bristol-Myers Squibb Anticancer Drugs Products, Services and Solutions
        7.6.4 Bristol-Myers Squibb Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.6.5 Bristol-Myers Squibb Recent Developments
    7.7 Amgen
        7.7.1 Amgen Profile
        7.7.2 Amgen Main Business
        7.7.3 Amgen Anticancer Drugs Products, Services and Solutions
        7.7.4 Amgen Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.7.5 Amgen Recent Developments
    7.8 AstraZeneca
        7.8.1 AstraZeneca Profile
        7.8.2 AstraZeneca Main Business
        7.8.3 AstraZeneca Anticancer Drugs Products, Services and Solutions
        7.8.4 AstraZeneca Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.8.5 AstraZeneca Recent Developments
    7.9 Merck & Co
        7.9.1 Merck & Co Profile
        7.9.2 Merck & Co Main Business
        7.9.3 Merck & Co Anticancer Drugs Products, Services and Solutions
        7.9.4 Merck & Co Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.9.5 Merck & Co Recent Developments
    7.10 Takeda
        7.10.1 Takeda Profile
        7.10.2 Takeda Main Business
        7.10.3 Takeda Anticancer Drugs Products, Services and Solutions
        7.10.4 Takeda Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.10.5 Takeda Recent Developments
    7.11 Merck KGaA
        7.11.1 Merck KGaA Profile
        7.11.2 Merck KGaA Main Business
        7.11.3 Merck KGaA Anticancer Drugs Products, Services and Solutions
        7.11.4 Merck KGaA Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.11.5 Merck KGaA Recent Developments
    7.12 Seagen
        7.12.1 Seagen Profile
        7.12.2 Seagen Main Business
        7.12.3 Seagen Anticancer Drugs Products, Services and Solutions
        7.12.4 Seagen Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.12.5 Seagen Recent Developments
    7.13 Eli Lilly
        7.13.1 Eli Lilly Profile
        7.13.2 Eli Lilly Main Business
        7.13.3 Eli Lilly Anticancer Drugs Products, Services and Solutions
        7.13.4 Eli Lilly Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.13.5 Eli Lilly Recent Developments
    7.14 Ono Pharmaceutical
        7.14.1 Ono Pharmaceutical Profile
        7.14.2 Ono Pharmaceutical Main Business
        7.14.3 Ono Pharmaceutical Anticancer Drugs Products, Services and Solutions
        7.14.4 Ono Pharmaceutical Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.14.5 Ono Pharmaceutical Recent Developments
    7.15 Pfizer
        7.15.1 Pfizer Profile
        7.15.2 Pfizer Main Business
        7.15.3 Pfizer Anticancer Drugs Products, Services and Solutions
        7.15.4 Pfizer Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.15.5 Pfizer Recent Developments
    7.16 GSK
        7.16.1 GSK Profile
        7.16.2 GSK Main Business
        7.16.3 GSK Anticancer Drugs Products, Services and Solutions
        7.16.4 GSK Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.16.5 GSK Recent Developments
    7.17 Exelixis
        7.17.1 Exelixis Profile
        7.17.2 Exelixis Main Business
        7.17.3 Exelixis Anticancer Drugs Products, Services and Solutions
        7.17.4 Exelixis Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.17.5 Exelixis Recent Developments
    7.18 Regeneron
        7.18.1 Regeneron Profile
        7.18.2 Regeneron Main Business
        7.18.3 Regeneron Anticancer Drugs Products, Services and Solutions
        7.18.4 Regeneron Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.18.5 Regeneron Recent Developments
    7.19 Innovent
        7.19.1 Innovent Profile
        7.19.2 Innovent Main Business
        7.19.3 Innovent Anticancer Drugs Products, Services and Solutions
        7.19.4 Innovent Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.19.5 Innovent Recent Developments
    7.20 Hengrui Medicine
        7.20.1 Hengrui Medicine Profile
        7.20.2 Hengrui Medicine Main Business
        7.20.3 Hengrui Medicine Anticancer Drugs Products, Services and Solutions
        7.20.4 Hengrui Medicine Anticancer Drugs Revenue (US$ Million) & (2019-2024)
        7.20.5 Hengrui Medicine Recent Developments

 8 Industry Chain Analysis
    8.1 Anticancer Drugs Industrial Chain
    8.2 Anticancer Drugs Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Anticancer Drugs Sales Model
        8.5.2 Sales Channel
        8.5.3 Anticancer Drugs Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Anticancer Drugs Market Trends
 Table 2. Anticancer Drugs Market Drivers & Opportunity
 Table 3. Anticancer Drugs Market Challenges
 Table 4. Anticancer Drugs Market Restraints
 Table 5. Global Anticancer Drugs Revenue by Company (2019-2024) & (US$ Million)
 Table 6. Global Anticancer Drugs Revenue Market Share by Company (2019-2024)
 Table 7. Key Companies Anticancer Drugs Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Anticancer Drugs Product Type
 Table 9. Key Companies Time to Begin Mass Production of Anticancer Drugs
 Table 10. Global Anticancer Drugs Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anticancer Drugs as of 2023)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Anticancer Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
 Table 14. Global Anticancer Drugs Sales Value by Type (2019-2024) & (US$ Million)
 Table 15. Global Anticancer Drugs Sales Value by Type (2025-2030) & (US$ Million)
 Table 16. Global Anticancer Drugs Sales Market Share in Value by Type (2019-2024)
 Table 17. Global Anticancer Drugs Sales Market Share in Value by Type (2025-2030)
 Table 18. Global Anticancer Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
 Table 19. Global Anticancer Drugs Sales Value by Application (2019-2024) & (US$ Million)
 Table 20. Global Anticancer Drugs Sales Value by Application (2025-2030) & (US$ Million)
 Table 21. Global Anticancer Drugs Sales Market Share in Value by Application (2019-2024)
 Table 22. Global Anticancer Drugs Sales Market Share in Value by Application (2025-2030)
 Table 23. Global Anticancer Drugs Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)
 Table 24. Global Anticancer Drugs Sales Value by Region (2019-2024) & (US$ Million)
 Table 25. Global Anticancer Drugs Sales Value by Region (2025-2030) & (US$ Million)
 Table 26. Global Anticancer Drugs Sales Value by Region (2019-2024) & (%)
 Table 27. Global Anticancer Drugs Sales Value by Region (2025-2030) & (%)
 Table 28. Key Countries/Regions Anticancer Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
 Table 29. Key Countries/Regions Anticancer Drugs Sales Value, (2019-2024) & (US$ Million)
 Table 30. Key Countries/Regions Anticancer Drugs Sales Value, (2025-2030) & (US$ Million)
 Table 31. AbbVie Basic Information List
 Table 32. AbbVie Description and Business Overview
 Table 33. AbbVie Anticancer Drugs Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Anticancer Drugs Business of AbbVie (2019-2024)
 Table 35. AbbVie Recent Developments
 Table 36. Johnson & Johnson Basic Information List
 Table 37. Johnson & Johnson Description and Business Overview
 Table 38. Johnson & Johnson Anticancer Drugs Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Anticancer Drugs Business of Johnson & Johnson (2019-2024)
 Table 40. Johnson & Johnson Recent Developments
 Table 41. Novartis Basic Information List
 Table 42. Novartis Description and Business Overview
 Table 43. Novartis Anticancer Drugs Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Anticancer Drugs Business of Novartis (2019-2024)
 Table 45. Novartis Recent Developments
 Table 46. Gilead Sciences Basic Information List
 Table 47. Gilead Sciences Description and Business Overview
 Table 48. Gilead Sciences Anticancer Drugs Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Anticancer Drugs Business of Gilead Sciences (2019-2024)
 Table 50. Gilead Sciences Recent Developments
 Table 51. Roche Basic Information List
 Table 52. Roche Description and Business Overview
 Table 53. Roche Anticancer Drugs Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Anticancer Drugs Business of Roche (2019-2024)
 Table 55. Roche Recent Developments
 Table 56. Bristol-Myers Squibb Basic Information List
 Table 57. Bristol-Myers Squibb Description and Business Overview
 Table 58. Bristol-Myers Squibb Anticancer Drugs Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Anticancer Drugs Business of Bristol-Myers Squibb (2019-2024)
 Table 60. Bristol-Myers Squibb Recent Developments
 Table 61. Amgen Basic Information List
 Table 62. Amgen Description and Business Overview
 Table 63. Amgen Anticancer Drugs Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Anticancer Drugs Business of Amgen (2019-2024)
 Table 65. Amgen Recent Developments
 Table 66. AstraZeneca Basic Information List
 Table 67. AstraZeneca Description and Business Overview
 Table 68. AstraZeneca Anticancer Drugs Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Anticancer Drugs Business of AstraZeneca (2019-2024)
 Table 70. AstraZeneca Recent Developments
 Table 71. Merck & Co Basic Information List
 Table 72. Merck & Co Description and Business Overview
 Table 73. Merck & Co Anticancer Drugs Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Anticancer Drugs Business of Merck & Co (2019-2024)
 Table 75. Merck & Co Recent Developments
 Table 76. Takeda Basic Information List
 Table 77. Takeda Description and Business Overview
 Table 78. Takeda Anticancer Drugs Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Anticancer Drugs Business of Takeda (2019-2024)
 Table 80. Takeda Recent Developments
 Table 81. Merck KGaA Basic Information List
 Table 82. Merck KGaA Description and Business Overview
 Table 83. Merck KGaA Anticancer Drugs Products, Services and Solutions
 Table 84. Revenue (US$ Million) in Anticancer Drugs Business of Merck KGaA (2019-2024)
 Table 85. Merck KGaA Recent Developments
 Table 86. Seagen Basic Information List
 Table 87. Seagen Description and Business Overview
 Table 88. Seagen Anticancer Drugs Products, Services and Solutions
 Table 89. Revenue (US$ Million) in Anticancer Drugs Business of Seagen (2019-2024)
 Table 90. Seagen Recent Developments
 Table 91. Eli Lilly Basic Information List
 Table 92. Eli Lilly Description and Business Overview
 Table 93. Eli Lilly Anticancer Drugs Products, Services and Solutions
 Table 94. Revenue (US$ Million) in Anticancer Drugs Business of Eli Lilly (2019-2024)
 Table 95. Eli Lilly Recent Developments
 Table 96. Ono Pharmaceutical Basic Information List
 Table 97. Ono Pharmaceutical Description and Business Overview
 Table 98. Ono Pharmaceutical Anticancer Drugs Products, Services and Solutions
 Table 99. Revenue (US$ Million) in Anticancer Drugs Business of Ono Pharmaceutical (2019-2024)
 Table 100. Ono Pharmaceutical Recent Developments
 Table 101. Pfizer Basic Information List
 Table 102. Pfizer Description and Business Overview
 Table 103. Pfizer Anticancer Drugs Products, Services and Solutions
 Table 104. Revenue (US$ Million) in Anticancer Drugs Business of Pfizer (2019-2024)
 Table 105. Pfizer Recent Developments
 Table 106. GSK Basic Information List
 Table 107. GSK Description and Business Overview
 Table 108. GSK Anticancer Drugs Products, Services and Solutions
 Table 109. Revenue (US$ Million) in Anticancer Drugs Business of GSK (2019-2024)
 Table 110. GSK Recent Developments
 Table 111. Exelixis Basic Information List
 Table 112. Exelixis Description and Business Overview
 Table 113. Exelixis Anticancer Drugs Products, Services and Solutions
 Table 114. Revenue (US$ Million) in Anticancer Drugs Business of Exelixis (2019-2024)
 Table 115. Exelixis Recent Developments
 Table 116. Regeneron Basic Information List
 Table 117. Regeneron Description and Business Overview
 Table 118. Regeneron Anticancer Drugs Products, Services and Solutions
 Table 119. Revenue (US$ Million) in Anticancer Drugs Business of Regeneron (2019-2024)
 Table 120. Regeneron Recent Developments
 Table 121. Innovent Basic Information List
 Table 122. Innovent Description and Business Overview
 Table 123. Innovent Anticancer Drugs Products, Services and Solutions
 Table 124. Revenue (US$ Million) in Anticancer Drugs Business of Innovent (2019-2024)
 Table 125. Innovent Recent Developments
 Table 126. Hengrui Medicine Basic Information List
 Table 127. Hengrui Medicine Description and Business Overview
 Table 128. Hengrui Medicine Anticancer Drugs Products, Services and Solutions
 Table 129. Revenue (US$ Million) in Anticancer Drugs Business of Hengrui Medicine (2019-2024)
 Table 130. Hengrui Medicine Recent Developments
 Table 131. Key Raw Materials Lists
 Table 132. Raw Materials Key Suppliers Lists
 Table 133. Anticancer Drugs Downstream Customers
 Table 134. Anticancer Drugs Distributors List
 Table 135. Research Programs/Design for This Report
 Table 136. Key Data Information from Secondary Sources
 Table 137. Key Data Information from Primary Sources
 Table 138. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Anticancer Drugs Product Picture
 Figure 2. Global Anticancer Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Anticancer Drugs Sales Value (2019-2030) & (US$ Million)
 Figure 4. Anticancer Drugs Report Years Considered
 Figure 5. Global Anticancer Drugs Players Revenue Ranking (2023) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Anticancer Drugs Revenue in 2023
 Figure 7. Anticancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 8. Cancer Immunotherapy Picture
 Figure 9. Targeted Therapy Picture
 Figure 10. Chemotherapy Picture
 Figure 11. Other Picture
 Figure 12. Global Anticancer Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 13. Global Anticancer Drugs Sales Value Market Share by Type, 2023 & 2030
 Figure 14. Product Picture of Lung Cancer
 Figure 15. Product Picture of Breast Cancer
 Figure 16. Product Picture of Prostate Cancer
 Figure 17. Product Picture of Blood-related Cancer
 Figure 18. Product Picture of Other
 Figure 19. Global Anticancer Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 20. Global Anticancer Drugs Sales Value Market Share by Application, 2023 & 2030
 Figure 21. North America Anticancer Drugs Sales Value (2019-2030) & (US$ Million)
 Figure 22. North America Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 23. Europe Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 24. Europe Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 25. Asia Pacific Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 26. Asia Pacific Anticancer Drugs Sales Value by Region (%), 2023 VS 2030
 Figure 27. South America Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 28. South America Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 29. Middle East & Africa Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 30. Middle East & Africa Anticancer Drugs Sales Value by Country (%), 2023 VS 2030
 Figure 31. Key Countries/Regions Anticancer Drugs Sales Value (%), (2019-2030)
 Figure 32. United States Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 33. United States Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 34. United States Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 35. Europe Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 36. Europe Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 37. Europe Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 38. China Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 39. China Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 40. China Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 41. Japan Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 42. Japan Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 43. Japan Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 44. South Korea Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 45. South Korea Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 46. South Korea Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 47. Southeast Asia Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 48. Southeast Asia Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 49. Southeast Asia Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 50. India Anticancer Drugs Sales Value, (2019-2030) & (US$ Million)
 Figure 51. India Anticancer Drugs Sales Value by Type (%), 2023 VS 2030
 Figure 52. India Anticancer Drugs Sales Value by Application (%), 2023 VS 2030
 Figure 53. Anticancer Drugs Industrial Chain
 Figure 54. Anticancer Drugs Manufacturing Cost Structure
 Figure 55. Channels of Distribution (Direct Sales, and Distribution)
 Figure 56. Bottom-up and Top-down Approaches for This Report
 Figure 57. Data Triangulation
 Figure 58. Key Executives Interviewed

Description

Anticancer drugs are medications used to treat cancer by targeting and killing cancer cells or inhibiting their growth. Anticancer drugs are medications specifically designed to combat cancer by either inhibiting the growth of cancer cells or inducing their death. These drugs operate through various mechanisms, such as disrupting the cell cycle, interfering with specific signaling pathways crucial for cancer cell survival, or targeting the blood vessels that support tumor growth. Anticancer drugs encompass a diverse range of classes, including cytotoxic drugs, targeted therapies, hormone therapies, immunotherapies, and angiogenesis inhibitors. The selection of these drugs depends on the type of cancer, its stage, and individual patient characteristics. While these medications play a crucial role in cancer treatment, they may also have side effects due to their impact on rapidly dividing normal cells.

 The global market for Anticancer Drugs was estimated to be worth US$ 190010 million in 2023 and is forecast to a readjusted size of US$ 390920 million by 2030 with a CAGR of 11.3% during the forecast period 2024-2030.

Global key players of Anticancer Drugs include Merck & Co, Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, etc. The top five players hold a share over 55%. North America is the largest market, and has a share about 55%, followed by Asia-Pacific and Europe with share 21% and 19%, separately. In terms of product type, Targeted Therapy is the largest segment, occupied for a share of 58%. In terms of application, Blood-related Cancer has a share about 23 percent.

The Anticancer Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anticancer Drugs.

Market Segmentation